In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reviewing 2005: The Top Biopharma Stories

Executive Summary

Among our stop stories from 2005: Safety and the FDA: decision by indecision; ahe Plan B kerfuffle; acquisition as the new exit strategy for private biotechs; TLRs-the hottest drug target; pricing revives vaccines; Pfizer's challenges and Genentech's triumphs. Among the predictions for the big stories of 2006: Medicare's impact, the oncology bubble, biogenerics and genomics' revival--via diagnostics.
Advertisement

Related Content

Pfizer's Change Management: Unfamiliar Faces
Biosimilars: The Time Has Come
The HPV Vaccine Race
Biosimilars: EMEA Wants Approvals
Pfizer-Vicuron: Fill Pipeline, Minimize R&D Expense
Pfizer Trims Altana From Pipeline
Pfizer's Analyst Day: And Now, For Its Next Trick
Pfizer/Angiosyn: Building Biotechs for Device-style Early M&A
The Buzz at JP Morgan--Biopharma: New Models Wanted
Finding the Opportunities in Aptamers

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002667

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel